UNIT · peptides · standard · freshness 90d
Sermorelin vs Tesamorelin — When to Use Which
Both are GHRH analogs; one is a short-acting compounded option, the other is the only FDA-approved GHRH for a specific lipodystrophy indication. How they differ in pharmacology, approved use, and current availability.
PREVIEW · free to read
Educational. Tesamorelin is a prescription drug. Sermorelin's regulatory status has shifted — see below. Nothing here is medical advice.
Both are GHRH analogs
Both stimulate the pituitary to release endogenous growth hormone via the GHRH receptor. Both maintain the natural pulsatile pattern of GH release (unlike exogenous somatropin), and both produce a downstream rise in IGF-1.
They differ in molecule, half-life, approval status, and clinical context.
Sermorelin (GRF 1-29)
- A 29-amino-acid fragment — the active N-terminal of native GHRH.
- Half-life: ~10–20 minutes.
- Originally FDA-approved (Geref) for pediatric growth hormone deficiency. The branded product was discontinued in 2008 for commercial reasons.
- Has been widely available through compounding pharmacies for off-label use in adult anti-aging contexts.
- As of 2023–2024, the FDA placed sermorelin on its restricted-for-compounding list. Legal compounded availability in the US has narrowed substantially.
Tesamorelin (Egrifta / Egrifta SV)
- A…
Pay with credits — log in or sign up at /account and use
Authorization: Bearer ck_… on
/api/units/sermorelin-vs-tesamorelin-2026. Or, for browser convenience:
Of every $0.0050, the producer earns 90% · Caiche keeps 10% as marketplace fee.
Browser purchase is a stub — replace with a real Stripe-funded credit balance for production use.
Sources
Related units
Nearest neighbours by topic similarity in the same corpus.
How CJC-1295 and ipamorelin work, why they are commonly stacked, what the published research supports, and the regulatory and safety picture as of 2026.
How the GLP-1 class has evolved through 2026 — single-pathway agonists (semaglutide), dual GLP-1/GIP (tirzepatide), and triple GLP-1/GIP/glucagon (retatrutide). Efficacy, side effects, and where each currently fits.
What TB-500 is, what the published research on Thymosin Beta-4 actually supports, the gap between the parent molecule and the truncated TB-500 fragment, and the regulatory and safety picture in 2026.
Summary of recent (late 2025 – early 2026) trial readouts for incretin-based metabolic drugs — retatrutide, ecnoglutide, mazdutide, MariTide. Efficacy, safety, and how they compare to semaglutide / tirzepatide.
Where the BPC-157 evidence base stands as of 2026 — animal data, limited human reports, common dosage patterns in research literature, and the regulatory and safety picture.
GET /api/units/sermorelin-vs-tesamorelin-2026
with Authorization: Bearer ck_… debits your balance and returns full content.